assess-demographic-covariate-effects

Solid

Assesses whether age, sex and body-size covariate effects on exposure are characterised, internally consistent, and traceable to their sources — the PopPK covariate analysis, any dedicated sub-study, the factor-coverage matrix and the labelling concept — and flags effects that are stated without a source, sourced but unstated, or stated inconsistently across documents. Use this skill when someone asks whether demographic covariates are adequately characterised for a programme, whether the age, weight or sex effects in a PopPK report match what the label says, or what demographic gaps remain before filing. Example: "Are age, weight and sex effects characterised for this compound?" Do not use for pharmacogenomic covariates, for renal or hepatic impairment, for drug-drug interactions, for selecting or adjusting a dose, or for any request to decide whether a covariate effect is clinically meaningful.

AI & Automation 6 stars 0 forks Updated 6 days ago MIT

Install

View on GitHub

Quality Score: 84/100

Stars 20%
28
Recency 20%
100
Frontmatter 20%
70
Documentation 15%
100
Issue Health 10%
80
License 10%
100
Description 5%
100

Skill Content

# Demographic Covariate Effects Assessment Assess the characterisation of age, sex and body-size covariate effects on drug exposure across a programme's evidence base — population PK covariate analyses, dedicated sub-studies, the factor-coverage matrix and the labelling concept — producing a reconciled register in which every stated effect carries its source and every source-identified effect carries its downstream statement. **This skill assesses characterisation completeness and traceability. It never decides that a covariate effect is clinically meaningful, selects or adjusts a dose, or determines that characterisation is sufficient for filing.** ## Who this is for Clinical pharmacology leads checking that demographic covariate effects are characterised and internally consistent before a submission · CP reviewers verifying that every demographic statement in the label traces to the PopPK or a dedicated study · regulatory writers who need each demographic claim source-linked. ## When to use this skill - "Are age, weight and sex effects characterised for this compound?" - "Does the PopPK covariate analysis cover all the demographic effects the label claims?" - "Which demographic covariates are still uncharacterised before we file?" - "Do the age and body-size statements in Section 8 match the PopPK report?" - "Reconcile the demographic covariate effects across the PopPK, CSR and 2.7.2" ## When NOT to use this skill These are close neighbours. Route them elsewhere and...

Details

Author
malekokour
Repository
malekokour/clinpharm-pmx-skills
Created
1 weeks ago
Last Updated
6 days ago
Language
Python
License
MIT

Similar Skills

Semantically similar based on skill content — not just same category

Code & Development Solid

assess-pharmacogenomic-evidence

Assesses whether pharmacogenomic covariate effects are characterised across the programme's evidence base — in-vitro enzyme and transporter genotype data, PopPK covariate analyses, dedicated PGx sub-studies, and the labelling concept — producing a gene-enzyme-phenotype register in which every stated PGx effect traces to its source and every source-identified polymorphism traces to its downstream statement. Use this skill when someone asks whether pharmacogenomic effects are characterised for a compound, whether a PopPK analysis covers the relevant polymorphisms, or what PGx gaps remain. Example: "Please pharmacogenomic effects are characterised for a compound." Do not use for demographic covariates (age, sex, body size), for organ-impairment characterisation, for drug-drug interaction assessment, or for any request to recommend a genotype-based dose adjustment.

6 Updated 6 days ago
malekokour
Data & Documents Solid

assess-special-population-strategy

Assesses the completeness and internal consistency of a programme's special-population evidence strategy — renal impairment, hepatic impairment, paediatrics, pregnancy and lactation, elderly, and other defined sub-populations — against the programme's declared scope, the target product profile, and the guidance-anchored criteria that create study or analysis obligations for each population. Use this skill when someone asks whether the special-population strategy covers what a reviewer will expect, which populations still need characterisation, or whether the strategy documents are internally consistent. Example: "Please the special-population strategy covers what a reviewer will expect, which populations still need characterisation." Do not use for reviewing one organ-impairment study report, for demographic covariate assessment in a PopPK, for pharmacogenomic characterisation, or for any request to decide whether a waiver rationale is sufficient or to commit to a study.

6 Updated 6 days ago
malekokour
Code & Development Solid

review-clinical-meaningfulness-covariate-effects

Reviews Clinical meaningfulness of covariate effects evidence pack for the L3 task «Clinical meaningfulness of covariate effects». Produces a source-linked finding register with denominators and an explicit refuse list. Use when a practitioner asks to work this topic — e.g. "Please review the materials for Clinical meaningfulness of covariate effects and produce a sourced finding register \u2014 do not decide the clinical or regulatory outcome.". Do not use to decide the outcome of clinical meaningfulness of covariate effects; approve or submit related documents; select or adjust a dose; speak for the sponsor to an agency.

6 Updated 6 days ago
malekokour